Keeping at least one meter apart and wearing face masks and eye protection are the best ways to cut the risk of COVID-19 infection, according to the largest review to date of studies on coronavirus disease transmission.

COVID-19 is many things. It is creating an economic impact like we have never seen before, it’s a lesson in basic hygiene, a test in societal patience, an enormous challenge, and a rare opportunity. It also demonstrates why many have chosen the pharmaceutical profession.

Mallinckrodt and Massachusetts General Hospital teamed up to evaluate the potential benefits of inhaled nitric oxide as a treatment for pulmonary complications in patients infected with COVID-19.

When COVID-19 first appeared in the news, scientists took note and began to prepare for a widespread outbreak. The general population, however, was not concerned. Many assumed COVID-19 would be like the SARS outbreak.

As the world tries to limit the spread of the novel coronavirus that causes COVID-19, there is some hope that warmer weather will cause the virus to dwindle, like what happens with seasonal influenza. Though research indicates that COVID-19 could be seasonal, returning in the fall.

Gilead Sciences has been overwhelmed with requests for remdesivir to treat cases of COVID-19, the disease caused by the novel coronavirus.

Johnson & Johnson announced that, although there have been anecdotal and unsubstantiated reports that darunavir – marketed by the company’s Janssen business unit as Prezista – is being used in treatment, there is no evidence that the HIV medicine has any effect against SARS-CoV-2.

Infections from China’s coronavirus spread to more than 8,100 people globally, surpassing the 2002-2003 SARS epidemic’s total in a fast-spreading health crisis forecast to pummel the world’s second-largest economy.

The toll from a new virus in China rose to six deaths and more than 300 cases as millions of Chinese prepared to travel for the Lunar New Year, heightening contagion risks.